{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:38:29Z","timestamp":1793723909777,"version":"4.6.1"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:p>This Viewpoint encourages investigators to move beyond FDA guidance toward patient-centered therapies and health equity for BCG-unresponsive bladder cancer.<\/jats:p>","DOI":"10.1001\/jamaoncol.2023.3304","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T15:32:26Z","timestamp":1694100746000},"page":"1491","source":"Crossref","is-referenced-by-count":4,"title":["Advancing Patient-Centered Outcomes and Equity in Clinical Trials for BCG-Unresponsive Nonmuscle Invasive Bladder Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Thomas J.","family":"Hwang","sequence":"first","affiliation":[{"name":"Division of Urological Surgery, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Cancer Innovation and Regulation Initiative, Dana-Farber Cancer Institute and Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Preston","sequence":"additional","affiliation":[{"name":"Division of Urological Surgery, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"cvp230013r1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle-invasive bladder cancer.","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"cvp230013r3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop.","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"issue":"16","key":"cvp230013r4","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group.","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"cvp230013r7","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1200\/JCO.2017.77.1592","article-title":"Efficacy, safety, and regulatory approval of Food and Drug Administration-designated breakthrough and nonbreakthrough cancer medicines.","volume":"36","author":"Hwang","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"cvp230013r9","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJMp2209043","article-title":"New federal incentives for diversity in clinical trials.","volume":"387","author":"Hwang","year":"2022","journal-title":"N Engl J Med"},{"key":"cvp230013r2","unstructured":"US Food and Drug Administration. BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment. Guidance for Industry, 2018. Accessed July 27, 2023. https:\/\/www.fda.gov\/media\/101468\/download?"},{"key":"cvp230013r5","unstructured":"National Comprehensive Cancer Network. NCCN guidelines. Accessed August 9, 2023. https:\/\/www.nccn.org\/guidelines\/nccn-guidelines"},{"key":"cvp230013r6","unstructured":"Hwang? TJ, Davies? BJ, Preston? MA. Additional References. Accessed July 27, 2023. https:\/\/tinyurl.com\/nmibcrefs?"},{"key":"cvp230013r8","unstructured":"University of Washington. CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer. Accessed July 27, 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03933826"},{"key":"cvp230013r10","unstructured":"US Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations: Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry. November 2020. Accessed August 9, 2023. https:\/\/www.fda.gov\/media\/127712\/download"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2809268\/jamaoncology_hwang_2023_vp_230013_1699901558.70554.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:06:35Z","timestamp":1700150795000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2809268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.3304","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}